August 20, 2026 Gubra Q2 2026 Visit Monitor for more information 1 Gubra Q2 2026 | Aug 20, 2026 08:00 Speakers Operator Adam Lange Head of Investor Relations | Gubra Markus Rohrwild Louise Dalbøge Thomas Langenickel Zoë Johnson Trine Nygaard Hamann…
August 20, 2026
Gubra
Q2 2026
Visit Monitor for more information
1
Gubra
Q2 2026 | Aug 20, 2026 08:00
Speakers
Operator
Adam Lange
Head of Investor Relations | Gubra
Markus Rohrwild
Louise Dalbøge
Thomas Langenickel
Zoë Johnson
Trine Nygaard Hamann
Kristian Borbos
Thomas Bowers
Rajan Sharma
CEO | Gubra
Chief Medical and Development Officer | Gubra
Head Gubra CRO | Gubra
Analyst | SEB
Chief Science Officer | Gubra
Head of Ventures and BD | Gubra
CFO | Gubra
Analyst | Goldman Sachs
Analyst
Visit Monitor for more information
2
Gubra
Q2 2026 | Aug 20, 2026 08:00
Prepared Remarks
Operator
Welcome to the conference call. For the first part of the conference call, the participants will be in listen-only mode. During the
questions and answers session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now
I will hand the conference over to the speakers. Please go ahead.
Adam Lange
Head of Investor Relations | Gubra
Good morning, everyone, and welcome to Gubra's Conference Call covering our First Half 2026 Results. My name is Adam, new
Head of Investor Relations at Gubra. Joining me today are members of Gubra's leadership team who will take you through key
developments for the company in the first six months of 2026 and our financial results. Following the presentation, we will open
the call for questions. Before we begin, I will just caution listeners on slide two here that we may make forward-looking
statements that are subject to risks and uncertainties. With that, I will hand over the call to our CEO, Markus, for opening
remarks.
Markus Rohrwild
CEO | Gubra
Thank you very much, Adam. Good morning, everyone. Welcome also from my side to our webcast. I would like to give a couple
of highlights of the company. In summary, I believe Gubra had a very good first half of the year across our entire business units.
Gubra Biotech significantly advanced our R&D pipeline and in the CRO, I think while we still have work to do, I see a promising
trend based on new commercial initiatives and also continued cost discipline. We have also now established a platform for
Gubra Ventures. This is a new business unit at Gubra, and we are currently evaluating multiple deals. Over the next couple of
months, I hope we can announce the first Gubra venture. At this point, I would like to remind you that our business model is
unique, based on three synergistic business units.
Markus Rohrwild
CEO | Gubra
Gubra Biotech discovers and develops new peptide therapeutics up to clinical proof of concept. Gubra Ventures invests in
exciting science adjacent to our flagship areas. Our CRO, while serving many external customers, is an integral and very
important part of our innovation in the biotech unit as well in our new ventures. Let me highlight a couple of milestones which
already have been achieved in the first half of the year. I am just going to mention three of them. AbbVie reported highly
encouraging phase I MAD results for the long-acting amylin. I think this is very robust data, and the start of the phase II is
imminent. Boehringer Ingelheim has already advanced the triple agonist in clinical phase II, and we now have initiated an
ambitious phase I/II-A trial for our fully owned GUB-UCN2 program, our new mega program. With this, I would like to hand over
to Louise.
Louise Dalbøge
Chief Science Officer | Gubra
Yeah. Thank you, Markus. Let's take a look at our streaMLine platform and how it enables our growing pipeline. At Gubra, we are
true experts in peptide drug discovery, and our core edge is that all the work we do is done using an in-house developed drug
discovery platform, streaMLine. The platform takes advantage of the AI-driven design and data analysis, and this is combined
with high throughput wet lab screening of multiple peptide libraries. We use multi-parameter optimization. What this means is
that we optimize all key drug properties at once. Ultimately, this enables us to save time and identify better molecules at speed.
The streaMLine platform has repeatedly delivered differentiated assets across a variety of therapeutic areas. What you see here
is the Gubra R&D pipeline. Since the last update, we have seen important progress.
Visit Monitor for more information
3
Gubra
Q2 2026 | Aug 20, 2026 08:00
Louise Dalbøge
Chief Science Officer | Gubra
First of all, we have seen the initiation of a GUB-UCN2 program entering phase I. Additionally, Boehringer Ingelheim has initiated
phase II development with the triple agonist and AbbVie still plans to initiate phase II in Q3. Simultaneously, Hemab has
expressed that they expect to initiate first in-human trials with HMB-003 in the second half of 2026. Likewise, we have
concluded the fourth collaboration project with Boehringer Ingelheim, a very early target discovery program. At Gubra, we have
been dedicated to treating and understanding obesity since the company's inception. Over the years, we have generated deep
scientific expertise all the way from discovery to clinical translation. Today, we will take a look at three of the most advanced
anti-obesity assets, so that each design with a differentiated profile compared to current standard of care and with blockbuster
potential.
Louise Dalbøge
Chief Science Officer | Gubra
Before getting into the data, let's just take a step back and take a broader look at the obesity landscape and where the market is
heading, because it's no secret that obesity continues to be a growing global healthcare challenge, and there is a wellrecognized need for novel treatment approaches. For the past decades, the core question with obesity treatment has really
been: Can we make patients lose weight? Can we achieve clinically meaningful weight loss? This has been the focus of the first
wave and has really been spearheaded by the first generation of incretin-based treatment. The focus on the current wave has
been to maximize body weight reduction and improve tolerability. Here we are seeing the introduction of complementary and
alternative mode of actions. We have seen the introduction of amylin analog as well as multimodal therapies, including DOR and
TL1A agonist.
Louise Dalbøge
Chief Science Officer | Gubra
The toolbox for patients have been significantly expanded here. It's also well acknowledged that the body weight reduction is not
just fat mass. Lean mass actually accounts for 20%-45% of the weight lost. Lean mass, it's muscle, it's bones, it's internal
organs, so it's all the tissue that we would ideally like to preserve when we are trying to lose weight. Therefore, we believe that
the focus for the next wave will be quality, with focus on body composition, maximizing fat mass loss, and preserve or even
enhance skeletal muscle mass. That's where the field is going, and Gubra's pipeline is strategically positioned to meet these
emerging trends. Now let's take a look at some of these assets. First of all, we have the TL1A agonist, long-acting, first-in-class.
Louise Dalbøge
Chief Science Officer | Gubra
This asset targets the GLP-1, the GLP and Y2 receptors to engage in complementary mode of action involved in body weight
reduction. This asset was discovered in collaboration with Boehringer Ingelheim, who now have sole responsibility for driving it
forward. After seeing encouraging phase I data that demonstrated a favorable safety and tolerability profile, along with
encouraging weight loss, Boehringer Ingelheim has now initiated the phase II development year. The study will enroll
approximately 300 participants and is treated for 42 weeks. We really see this as a true validation of both the asset's potential,
but also Gubra's peptide discovery capabilities. Next we have ABBV-295, the long-acting amylin analog that is now out-licensed
to AbbVie. A core differentiator with the amylin class of compounds is the potential to deliver clinically relevant weight loss with
a better tolerability profile.
Louise Dalbøge
Chief Science Officer | Gubra
This means that amylin may represent the next distinct class of drugs for chronic weight management. 295 has consistently
shown competitive results throughout a comprehensive phase I program. The data from the MAD study was the top line data
was presented by AbbVie in March, and here 295 showed a very competitive weight loss profile of almost 10% after just 12
weeks of treatment. Remember that this is in a lower BMI cohort with predominantly male participants. Importantly, 295 also
revealed the potential for less frequent dosing. Here, comparable weight loss was observed with the every second weekly
dosing or even once monthly dosing. In addition, 295 had a favorable safety and tolerability profile. Adverse events were
predominantly GI, mild and transient. The data from this study will be presented at EASD in September.
Louise Dalbøge
Chief Science Officer | Gubra
Currently, 295 is being tested in an ongoing phase I-B trial in people with obesity, higher BMI range, and higher proportion of
female participants. AbbVie still plans to initiate phase II in Q3. With that, I'm happy to hand over to Thomas, our CMDO, who will
talk more about our GUB-UCN2 program.
Visit Monitor for more information
4
Gubra
Q2 2026 | Aug 20, 2026 08:00
Thomas Langenickel
Chief Medical and Development Officer | Gubra
Thank you, Louise. Now let me turn to what makes the GUB-UCN2 so compelling. GUB-UCN2 is a long-acting agonist at the
CRHR2 receptor, and that makes it really a very differentiated and novel mechanism of action that addresses key needs for
people living with obesity. As you can see on this slide, in adipose tissue, GUB-UCN2 lowers fat mass and lowers triglycerides. In
the muscle tissue, which is actually the main tissue, the main target tissue for GUB-UCN2, it drives the buildup of muscle
through anabolic and inhibition of catabolic effect, which also has a positive impact on insulin sensitivity. Further evidence really
points towards additional cardiorenal benefits as laid out on the slide. For me, there are actually two key takeaways on that
slide. First, GUB-UCN2 is not really simply about weight loss. Yeah.
Thomas Langenickel
Chief Medical and Development Officer | Gubra
It really has the potential to fundamentally improve body composition by reduction of fat mass and by building muscle mass at
the same time. The added muscle mass is really expected to provide functional benefit to patients through improvement of
strength and physical performance. That really opens up two really compelling and attractive development path. On one hand,
using GUB-UCN2 as a differentiated monotherapy, on the other hand, in conjunction with incretin-based therapies. The second
key takeaway is that the opportunity is not about obesity alone. As I indicated, we have multiple effects on very differentiated
tissues, which gives us the opportunity to develop GUB-UCN2 into multiple indications, in particular, if you are thinking about
muscle wasting conditions and cardiovascular diseases, which gives GUB-UCN2 really a very broad development potential. The
preclinical data generated to date make the potential really tangible.
Thomas Langenickel
Chief Medical and Development Officer | Gubra
I would like to share a dataset with you, really as an example of a use case for GUB-UCN2, where we investigated it as
monotherapy and in combination with semaglutide in rats with obesity due to high-fat diet. On the left-hand side, you can see
that GUB-UCN2 really profoundly reduces fat mass, which is depicted by the green bar. When combined with semaglutide, we do
see an additive effect beyond the effect that we do see with either treatment alone. The middle graph shows really the
differentiation of GUB-UCN2. We do see that with this mechanism of action, we can really build lean mass, of which muscle is
really a predominant part. We can also rescue the loss of muscle mass that we see with semaglutide in this experimental
setting.
Thomas Langenickel
Chief Medical and Development Officer | Gubra
On the right-hand side, you see actually very nicely why body weight does not tell the full story. Monotherapy alone does not
result in a reduction in body weight in this particular experimental setting, and that is because we reduce body fat and at the
same time balance it with a gain in fat muscle mass. Hence, the overall effect in this setting is neutral. However, when combined
with semaglutide, we continue seeing the weight reduction driven by semaglutide, but GUB-UCN2 really dramatically changes
the composition of the weight loss that we are seeing in combination therapy. This is really a very, very attractive drug profile,
right? Reducing fat mass, improving muscle mass, and having the potential for a functional muscle improvement. We are very
excited about now moving this asset into clinical development, and it is really an important inflection point for Gubra, right?
Thomas Langenickel
Chief Medical and Development Officer | Gubra
Moving a compelling preclinical package into a clinical opportunity. We have now initiated a very comprehensive phase I, phase
II-A clinical trial where we involve healthy participants, but also people living with obesity, and move the assessment from the
single ascending dose to a multiple ascending dose and a multiple dose part with up to 16 weeks of treatment duration.
Importantly, we are assessing GUB-UCN2 as monotherapy and as combination therapy with an incretin. In addition to the typical
phase I endpoints related to safety tolerability and pharmacokinetics, the trial was really designed from the outset to provide a
very comprehensive clinical data package, looking at muscle mass and muscle function, and also building the foundation really
for indication expansion into muscle wasting conditions and into cardiovascular diseases.
Thomas Langenickel
Chief Medical and Development Officer | Gubra
We will be able to speak more about the development program of GUB-UCN2 at our upcoming R&D event on October 27th. With
that, I would like to conclude and hand it over to Zoë, our Head of Gubra Ventures.
Visit Monitor for more information
5
Gubra
Q2 2026 | Aug 20, 2026 08:00
Zoë Johnson
Head of Ventures and BD | Gubra
Thank you, Thomas. Now we turn to Gubra Ventures, which is our value accelerator, and the message here is simple. We are
using our internal engine to create additional routes to value via external innovation. Why are we doing this? Gubra Ventures is
built around four value accelerators. The first is increasing shots on goal by accessing external innovation, including novel
assets and novel technologies that are complementary to Gubra's core. The second is expansion into new diseases and new
technology areas. The third is return via future exits through additional revenue stream beyond that of the CRO and the biotech
pipeline. The fourth is because this will not be a standing start, that we can go faster, we can lower our dependencies on
external service providers, and we can also use disciplined capital use to create these opportunities. Why now?
Zoë Johnson
Head of Ventures and BD | Gubra
Gubra is really uniquely positioned to build on the credible foundations that we've built and amplify those to produce these value
accelerators. The first foundation is our scientific and therapeutic area depth as well as our development capabilities. Secondly,
we have a discovery platform that we can use for joint ventures to create new opportunities in the peptide therapeutic space.
Third, we'll use our integrated capabilities, know-how, and shared infrastructure to bring those opportunities faster to the clinic.
In all these respects, Gubra Ventures will be bringing more than capital. In summary, we're expanding our innovation footprint by
additional routes to return and turning what we do well into further value creation. With that, I'll pass over to Trine.
Trine Nygaard Hamann
Head Gubra CRO | Gubra
Thank you so much for that, Zoë. The CRO is continuously an important value enabler for Gubra. For many years, we've had a
strong record of solid growth and profitability, building best-in-class services for serving our customers, both externally and
internally. We are considered a scientific leader. We have more than 18 years experience working in the metabolic space and, in
particular, in obesity, and we serve 17 of the top 20 pharmas globally. They really choose us because we can deliver complex
models with high-quality, unbiased data at speed and with excellent scientific guidance. Our ambition is really to stay ahead of
the curve. We've done that always in the past, introducing obesity services very early on, MASH and kidney platforms.
Trine Nygaard Hamann
Head Gubra CRO | Gubra
And now we have introduced this year services in women's health and sarcopenia, so this muscle platform, and really trying to
differentiate ourselves, and open up new growth opportunities for the future. So it's this combination of deep scientific expertise
and the trusted customer relationship and continuous service innovation that underpins the long-term strength of the CRO
business. After a few challenging quarters, we are seeing early signs of improvement across a number of different market
indicators. In particular, biotech funding has rebounded strongly in 2026, and we also see a continued outsourcing trend among
pharma companies especially, and this is really driving demand in our industry. We have clear priorities. We want to maintain our
leading position in the metabolic and fibrotic space.
Trine Nygaard Hamann
Head Gubra CRO | Gubra
We want to also, as I said, expand into new, interesting, and attractive therapeutic areas and accelerate the development of the
commercialization of our advanced 2D and 3D imaging platforms. Besides that, we are also increasing our commercial
activities, in particular in U.S., we are expanding. Combining this with a cost discipline, we really focus on regaining momentum.
We've grown 11% since second half of 2025, and we've also returned to positive profitability. So there's naturally some
uncertainty around the revenue recognition, but we see a very sound order book both with our external and internal customers.
Obesity remains our largest contributor revenue-wise, and we see a rebound in MASH and kidney studies, which is improving the
commercial outlook for second half of the year.
Trine Nygaard Hamann
Head Gubra CRO | Gubra
So overall, we are cautiously optimistic about the next half year, and we want to convert this momentum that we're having now
into profitable growth while continuing to strengthen the strategic importance of the CRO for the business. And now I will hand it